TY - JOUR
T1 - Antibiotics inhibit tumor and disease activity in cutaneous T cell lymphoma
AU - Lindahl, Lise M
AU - Willerslev-Olsen, Andreas
AU - Gjerdrum, Lise M R
AU - Nielsen, Pia R
AU - Blümel, Edda
AU - Rittig, Anne H
AU - Celis, Pamela
AU - Herpers, Bjorn
AU - Becker, Jürgen C
AU - Stausbøl-Grøn, Birgitte
AU - Wasik, Mariusz A
AU - Gluud, Maria
AU - Fredholm, Simon
AU - Buus, Terkild B
AU - Johansen, Claus
AU - Nastasi, Claudia
AU - Peiffer, Lukas
AU - Kubat, Linda
AU - Bzorek, Michael
AU - Eriksen, Jens O
AU - Krejsgaard, Thorbjørn
AU - Bonefeld, Charlotte M
AU - Geisler, Carsten
AU - Mustelin, Tomas
AU - Langhoff, Erik
AU - Givskov, Michael
AU - Woetmann, Anders
AU - Kilian, Mogens
AU - Litman, Thomas
AU - Iversen, Lars
AU - Odum, Niels
N1 - Copyright © 2019 American Society of Hematology.
PY - 2019/9/26
Y1 - 2019/9/26
N2 - It has been proposed that CD4 T-cell responses to Staphylococcus aureus (SA) can inadvertently enhance neoplastic progression in models of skin cancer and cutaneous T-cell lymphoma (CTCL). In this prospective study, we explored the effect of transient antibiotic treatment on tumor cells and disease activity in 8 patients with advanced-stage CTCL. All patients experienced significant decrease in clinical symptoms in response to aggressive, transient antibiotic treatment. In some patients, clinical improvements lasted for more than 8 months. In 6 of 8 patients, a malignant T-cell clone could be identified in lesional skin, and a significant decrease in the fraction of malignant T cells was observed following antibiotics but an otherwise unchanged treatment regimen. Immunohistochemistry, global messenger RNA expression, and cell-signaling pathway analysis indicated that transient aggressive antibiotic therapy was associated with decreased expression of interleukin-2 high-affinity receptors (CD25), STAT3 signaling, and cell proliferation in lesional skin. In conclusion, this study provides novel evidence suggesting that aggressive antibiotic treatment inhibits malignant T cells in lesional skin. Thus, we provide a novel rationale for treatment of SA in advanced CTCL.
AB - It has been proposed that CD4 T-cell responses to Staphylococcus aureus (SA) can inadvertently enhance neoplastic progression in models of skin cancer and cutaneous T-cell lymphoma (CTCL). In this prospective study, we explored the effect of transient antibiotic treatment on tumor cells and disease activity in 8 patients with advanced-stage CTCL. All patients experienced significant decrease in clinical symptoms in response to aggressive, transient antibiotic treatment. In some patients, clinical improvements lasted for more than 8 months. In 6 of 8 patients, a malignant T-cell clone could be identified in lesional skin, and a significant decrease in the fraction of malignant T cells was observed following antibiotics but an otherwise unchanged treatment regimen. Immunohistochemistry, global messenger RNA expression, and cell-signaling pathway analysis indicated that transient aggressive antibiotic therapy was associated with decreased expression of interleukin-2 high-affinity receptors (CD25), STAT3 signaling, and cell proliferation in lesional skin. In conclusion, this study provides novel evidence suggesting that aggressive antibiotic treatment inhibits malignant T cells in lesional skin. Thus, we provide a novel rationale for treatment of SA in advanced CTCL.
U2 - 10.1182/blood.2018888107
DO - 10.1182/blood.2018888107
M3 - Journal article
C2 - 31331920
SN - 0006-4971
VL - 134
SP - 1072
EP - 1083
JO - Blood
JF - Blood
IS - 13
ER -